A company you can rely on
Founded in 1922, Thornton & Ross Ltd is one of the largest OTC pharmaceutical manufacturers in the UK and exports to over 80 countries worldwide.
We continue to grow our business every year in the UK and International markets by innovation and acquisition. Following the company’s acquisition by the STADA group Thornton & Ross has merged with Genus Pharmaceuticals.
From a base in Huddersfield, West Yorkshire, Thornton & Ross develop, manufacture and supply a wide and growing range of branded OTC medicines, dermatological preparations, niche generic medicines and other pharmaceutical, healthcare and hygiene products.
Our product portfolio encompasses a large number of well-known OTC brands such as Covonia®, Hedrin®, Care®, Cetraben®, Movelat®, Radian B® and Setlers®, as well as the UK's leading disinfectant Zoflora®.
We also own the Flexitol® brand in the UK and Eire.
Our values reflect our roots as a family-owned business and we continue to combine the highest professional standards with traditional levels of care.
Our approach is to combine good, responsive customer service and quality products, in a working environment that encourages innovation.
Part of the STADA group
Thornton & Ross is owned by Frankfurt based STADA Arzneimittel AG
STADA is a pan-European pharmaceutical company that develops, manufactures, markets and distributes branded and generic pharmaceutical products. With sales of over two billion Euros, STADA affords Thornton & Ross with both research and development support and financial investment.
Thornton & Ross has become the Centre of Excellence within the STADA group in order to promote the development of OTC and Dermatology business.
An essential factor for the continued success of STADA's business model is its individual market focus through the international network of local marketing and sales companies. In order to rapidly adapt to individual country healthcare market changes, STADA's local sales companies retain a high level of autonomy, allowing the flexibility to adapt and capitalise on local country market opportunities.
Gender Pay Gap 2017
In 2017, the Government brought in legislation which requires all organisations with more than 250 employees to publish a Gender Pay Gap report. Click here for that report.
News
Leading pharmaceutical company invests in seven-figure state-of-the-art facility
Huddersfield pharmaceutical company Thornton & Ross is expanding, with a new seven-figure state-of-the-art facility due to open at the beginning of January.
Thornton & Ross triumphant in industry awards
Huddersfield-based pharmaceutical company Thornton & Ross has received national recognition for six of its products at the national 2019 ‘Most Valuable Product’ (MVP) Awards in pharmacy.
Thornton & Ross launches alternative, cost-effective treatment for osteoporosis in UK
West Yorkshire-based pharmaceutical company Thornton & Ross (T&R) is launching an alternative, cost-effective treatment for osteoporosis.
Thornton & Ross to acquire established GSK Consumer Health brands
Thornton & Ross has expanded its Consumer Health business with a contract to acquire four UK skin care brands, as well as a paediatric cough remedy, from GlaxoSmithKline. Completion of the deal is expected to occur by August 2019.
Peter Goldschmidt to succeed Claudio Albrecht as STADA’s CEO
STADA Arzneimittel AG Appoints Peter Goldschmidt as CEO to suceed Claudio Albrecht.
STADA acquires EMEA rights to global anti-dandruff brand Nizoral from Janssen Pharmaceutica
STADA Arzneimittel AG is further strengthening its position in branded over-the-counter healthcare products.
Ladival wins 'Best Beach Sun Protection 2017'
Thornton & Ross is pleased to announce that Ladival Sun Protection Lotion SPF30 has won the 'Best Beach Sun Protection' in this year's Best Beauty by Stylist Awards 2017.
Thornton & Ross Ltd signs licensing agreement with Futura Medical
Thornton & Ross is pleased to announce it has entered in to a long-term licensing agreement with Futura Medical.
>> News Archive
